Benitec Biopharma Inc. (BNTC) is a Biotechnology company in the Healthcare sector, currently trading at $13.25. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is BNTC = $27 (+103.8% upside).
Valuation: BNTC trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 6.05.
Net income is $38M (loss), growing at -30.3%/yr. Net profit margin is 0% (thin). Gross margin is 50% (-37.7 pp trend).
Balance sheet: total debt is $849,000 against $97M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 54.67 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $100M.
Analyst outlook: 6 / 7 analysts rate BNTC as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
